Moeremans Karen, Annemans Lieven
HEDM-IMSHealth, Crayerstraat 6, 1000 Brussels, Belgium.
Expert Opin Pharmacother. 2006 Oct;7(14):1931-43. doi: 10.1517/14656566.7.14.1931.
Systemic fungal infections in neutropenic patients remain a clinical problem that is associated with morbidity and mortality. Continuing efforts are being made to develop improved (i.e., more effective or safe) drugs, and several new treatments have recently become available. These have increased the therapeutic options available to clinicians to address the problem of systemic fungal infections. Therapeutic choices are difficult when taking into account aspects of efficacy, safety and costs that are associated with the available alternatives. This review summarises the present status of health economic knowledge of the standard therapies that have been available for many years, and also reports on the most recent health economic evidence available for the newly developed treatment alternatives.
中性粒细胞减少患者的系统性真菌感染仍然是一个与发病率和死亡率相关的临床问题。人们一直在不断努力开发改良（即更有效或更安全）的药物，最近已有几种新疗法可供使用。这些新疗法增加了临床医生应对系统性真菌感染问题的治疗选择。在考虑现有替代方案的疗效、安全性和成本等方面时，治疗选择颇具难度。本综述总结了已应用多年的标准疗法的卫生经济学知识现状，同时也报告了新开发的替代治疗方案的最新卫生经济学证据。
